Maha CET Cell Extends NEET 2025 Counselling Registration Deadline

Maharashtra- Maharashtra CET Cell has extended the last date to register for National Eligibility and Entrance Test-Undergraduate (NEET UG) counselling for the academic year 2025. This will give more time to the students applying for admission to MBBS, BDS, BAMS, BUMS, BHMS and other health science courses in medical colleges of Maharashtra. With this, students can now register for counselling till August 4, 2025.

In this regard, the Maharashtra Common Entrance Test Cell (MHCETC) has issued a notice informing that the the Medical Counselling Committee (MCC) has granted the extension for All India Quota Counselling. Therefore, the State CET Cell has decided to extend the registration period and revise the CAP (Centralized Admission Process) schedule accordingly.

As per the revised schedule, the Online Registration and Session Apply (Common for All Courses) is now extended upto 04 August 2025 and the payment of the registration fees upto 05 August 2025. Below is the detailed schedule-

SCHEDULE

S.NO

ACTIVITY

DATE & TIME

1

Online Registration and Session Apply (Common for All Courses) {MBBS/ BDS/ BAMS/ BHMS/ BUMS/ BNYS/ BPTH/ BOTH/ BASLP/ B(P&O}.

Extended upto 04 August 2025 upto 11:59 pm (server Time)

2

Payment of Registration Fees through Online Payment Gateway for {MBBS/ BDS/ BAMS/ BHMS/ BUMS/ BNYS/ BPTH/ BOTH/ BASLP/ B(P&O} after session apply (A candidate will be treated as registered for the process only after successful Payment of the fees.)

Extended upto 05 August 2025 upto 11:59 pm (server Time)

3

Uploading of colored scanned copy of Original Requisite Documents on portal as per the list.

Extended upto 05 August 2025 upto 11:59 pm (server Time)

4

Publication of Registered Candidate List.

06 August 2025

CAP ROUND 1 GROUP A-MBBS & BDS COURSES ONLY

S.NO

ACTIVITY

DATE & TIME

1

Publication of Provisional Merit List of registered candidates for MBBS/BDS course only.

06 August 2025

2

Publication of Seat Matrix for MBBS/BDS Only.

06 August 2025

3

Online Filling of Preference Form MBBS/BDS Only.

06 August 2025 after 03:00 pm to 09 August 2025 upto 11:59 pm.

4

Declaration of CAP Round – 1 Selection List MBBS/BDS Only.

11 August 2025

5

Physical Joining and Filling of Status Retention Form with All Original Documents & Requisite Fees by DD/Cheque.

12 to 17 August 2025 upto 05:30 pm (Excluding 15/08/2025) .

IMPORTAN POINTS

1 Candidates should upload all the requisite original scanned documents.

2 It will be the sole responsibility of the candidate to upload all the necessary documents and familiarize herself/himself with online preference filling system for admission to Health Science Courses.

3 Candidates should also ascertain her/his eligibility for admission to the various courses before filling up the registration form.

4 PWD candidates should have claimed the quota at the time of NEET. They should submit Online PWD certificate issued by any one of the 16 boards.

5 Candidates belonging to reservation category must claim so in the application form before submitting the same.

6 Any claim for converting from Open/General category to reserved category after submission and payment shall not be entertained.

7 NRI candidate should register on Foreign Candidate Registration Portal before 03/08/2025 for verification of candidate’s eligibility. The subsequent schedule will be as above.

8 NRI candidates should note that they are eligible only for 15% Institute Quota as per merit.

To view the schedule, click the link below

https://medicaldialogues.in/pdf_upload/maharashtra-cet-cell-extends-neet-2025-counselling-registration-deadline-till-august-4-296672.pdf

Powered by WPeMatico

Health Ministry Notifies Cosmetics Rules 2025, Empowers States To Suspend Licences

New Delhi: The Ministry of Health and Family Welfare has notified the Cosmetics (Amendment) Rules, 2025, making several key changes to the Cosmetics Rules, 2020, including clarification on expiry labelling, redefining regulatory terminology, updated recordkeeping norms, and introducing a new provision for licence cancellation or suspension.

The notification, published as G.S.R. 513(E) in the Gazette of India on 29th July 2025, states:

“Now, therefore, in exercise of the powers conferred by section 12 and section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government, after consultation with the Drugs Technical Advisory Board, hereby makes the following rules to amend the Cosmetics Rules, 2020.”

One of the significant changes is the insertion of a clear definition regarding expiry labels:

“For the purposes of this clause, the expression ‘use before’ means, use before the first day of a month mentioned on label and the expression ‘date of expiry’ mean the cosmetic expires on the last day of the month.”

The amendment also replaces the term “controlling officer” with “Controlling Authority” across multiple rules including Rules 6, 9, and 31(2). Further, Rule 7 has been substituted entirely to clarify that:

“The Government Analyst appointed under section 20 of the Act (23 of 1940) shall be the Government Analyst for the purposes of these rules.”

A major structural change has been introduced with the insertion of Rule 31A titled “Cancellation or suspension of licence.” It empowers the State Licensing Authority to cancel or suspend a licence in case of violations, stating:

“If a licensee fails to comply with any of the conditions of license or with any provision of the Act or the rules made thereunder, the State Licensing Authority may… cancel a licence issued under these rules or suspend it… wholly or in respect of some of the substances to which it relates.”

It also allows for an appeal:

“A licensee whose licence has been suspended or cancelled, may, within a period of ninety days… appeal to the State Government… and the order… shall be final.”

In another key compliance update, new clauses under Rule 26 mandate that:

“The licensee shall keep record of the details of each batch of cosmetic manufactured and of the raw materials used therein… and such records shall be retained for a period of three years or six months after expiry of the batch whichever is later.”

“The licensee shall test each batch or lot of the raw materials used… and also each batch of final product… and shall maintain records… retained for a period of three years or six months after expiry…”

However, these provisions exempt soap manufacturers:

“Provided that clauses (f) and (h) shall not apply to the manufacture of soap… approved by the Licensing Authority.”

Among other changes:

1. Rule 11 now designates the Central Drugs Laboratory to also serve as the Central Cosmetics Laboratory for analysis and appellate functions.

2. In cases of export, Rule 34(10) has been revised to clarify that:

“The label on package or container of cosmetic shall comply with the law of the country to which the cosmetic is to be exported… where a cosmetic is required by the consignee to be not labeled with the name and address of the manufacturer, the label… shall bear a code number as approved by the State Licensing Authority.”

Several terminologies across the rules have also been aligned—replacing “licence” with “approval,” and “licensed premises” with “approved premises,” in relevant provisions, including Rules 60, 61, and 62. Additionally, courier-based provisions in Rule 49 have been omitted.

The notification concludes:

“The principal rules were published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i) vide notification number G.S.R.763 (E), dated the 15th December, 2020.”

To view the original Gazette, click on the link below:

Powered by WPeMatico

Rs 76 lakh compensation slapped on 6 Doctors, hospital for medical negligence

Rs 76 lakh compensation slapped on 6 Doctors, hospital for medical negligence

The District Consumer Disputes Redressal Commission, Thanjavur, recently directed a Tambaram-based private hospital and its six doctors (including an orthopaedic surgeon, a surgeon, 3 Anaesthetists, and a plastic surgeon) to pay Rs 76 lakh compensation to a patient, who became disabled after undergoing treatment at the hospital.

After undergoing six surgeries at the hospital, the complainant/patient was diagnosed with a compartment syndrome and foot drop. The complainant became 50% disabled, requiring the assistance of a round-the-clock attendant.

The history of the case goes back to 2022, when, after meeting with a two-wheeler accident, the complainant was diagnosed with a fracture in his right knee. On the same day i.e. 15.09.2022, the complainant was admitted to Kasthuri Hospital, Thambaram. The doctors diagnosed a normal ECG, a normal Doppler study of the right lower limb arteries, no evidence of stenosis in the arteries, and right lower limb no deep vein thrombosis. After assessing the complainant, the treating doctor- an orthopaedic surgeon, found no signs of compartment syndrome.

For more information, click on the link below:

Rs 76 lakh compensation slapped on 6 Doctors, hospital for medical negligence

Powered by WPeMatico

AIIMS Patna Resident doctors accuse MLA of assault, go on strike

AIIMS Patna Scuffle: Resident doctors strike over alleged MLA Misconduct

Resident doctors at the All India Institute of Medical Sciences (AIIMS) Patna went on a strike on Friday against the alleged manhandling of hospital staff by Sheohar MLA Chetan Anand. The incident reportedly escalated into a scuffle after the MLA’s supporters allegedly attempted to enter the hospital premises. When security personnel attempted to stop them, a heated exchange broke out between the two sides.

Healthcare services were affected at AIIMS Patna on Friday as resident doctors boycotted work in protest against the alleged high-handedness of Sheohar MLA Chetan Anand.

In a letter to the medical superintendent of AIIMS Patna, the Resident Doctors’ Association (RDA) sought legal action against Anand and the deployment of security personnel on the hospital premises.

“The MLA, his wife and his armed guards forcibly entered the hospital area, physically assaulted security staff, threatened resident doctors with death and brandished a firearm within hospital premises. A hospital guard was brutally injured and resident doctors were subjected to threats and abuse inside their own workplace,” the RDA alleged in the letter, according to a PTI news report.

For more information, click on the link below:

AIIMS Patna Scuffle: Resident doctors strike over alleged MLA Misconduct

Powered by WPeMatico

No report on Bias or transparency issues in NMC: Health Minister Tells Parliament

New Delhi: Responding to the concerns raised on the alleged lack of transparency in the National Medical Commission (NMC) and the possible bias in favour of the doctors at the expense of the patients, the Minister of State for Health, Smt. Anupriya Patel refuted such claims and stated that “No such report has been received in the Ministry of Health and Family Welfare.”

Further, the MoS Health informed the Parliament that the Ethics Board of NMC regulates the professional conduct and promotes medical ethics amongst doctors and the mechanism to handle complaint (s) with regard to professional misconduct by doctors are provided under Clause 8.2 of the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002.

The Minister was responding to questions raised by Dr. M. Thambidurai, who sought to know if the Government was aware of the reports stating that NMC lacks transparency and is biased in favour of doctors at the expense of patients. He also sought to know the steps taken by the Government to ensure that NMC functions transparently and fairly.

Also Read: Patients can file appeals against state medical councils orders: NMC

In response, MoS Health Smt Patel informed, “No such report has been received in the Ministry of Health and Family Welfare. Further, the Ethics and Medical Registration Board (EMRB) of National Medical Commission (NMC) regulates the professional conduct and promotes medical ethics amongst the medical professionals. Further, Clause 8.2 of Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002 provides for a mechanism to handle complaint(s) with regard to professional misconduct by the medical professional (s).”

“To ensure that the NMC functions in a transparent and fair manner, the Central Government appoints amongst others the Chairperson, Presidents of four Autonomous Boards as per the NMC Act, 2019 and Rules made their under. Also, as per Section 4 of the said Act, there are ten ex-officio Members in the Commission which also include heads of medical institutions of national repute. NMC also has twenty-two part-time members drawn from States and elected members of the State Medical Councils,” Minister Patel further added.

As per Clause 8.2 of Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, “any complaint with regard to professional misconduct can be brought before the appropriate Medical Council for Disciplinary action. Upon receipt of any complaint of professional misconduct, the appropriate Medical Council would hold an enquiry and give opportunity to the registered medical practitioner to be heard in person or by pleader. If the medical practitioner is found to be guilty of committing professional misconduct, the appropriate Medical Council may award such punishment as deemed necessary or may direct the removal altogether or for a specified period, from the register of the name of the delinquent registered practitioner. Deletion from the Register shall be widely publicized in local press as well as in the publications of different Medical Associations/ Societies/Bodies.”

Previously, under Section 8.8 of the MCI Ethics Regulations 2002, any person (doctors or non medical professionals) could challenge the decision of the State Medical Council before the Apex Medical Commission.

However, after NMC replaced the erstwhile Medical Council of India (MCI), it has reportedly been rejecting patients’ appeals stating that only medical practitioners could file an appeal before the NMC under the NMC Act 2019.

Section 30(3) of the NMC Act 2019 which states, “(3) A medical practitioner or professional who is aggrieved by any action taken by a State Medical Council under sub-section (2) may prefer an appeal to the Ethics and Medical Registration Board against such action, and the decision, if any, of the Ethics and Medical Registration Board thereupon shall be binding on the State Medical Council, unless a second appeal is preferred under sub-section (4).”

Also Read: Patient’s appeal allowed or not? Confusion persists over NMC rejection

Powered by WPeMatico

Additional Professor Post At AIIMS Jodhpur, Applications Open! Here’s HOW To APPLY

Jodhpur: The All India Institute of Medical Sciences (AIIMS Jodhpur) has invited online applications for the Retired Faculty post on a Contract Basis.

AIIMS Jodhpur is one of the 6 new AIIMS established by the Ministry of Health & Family Welfare, Government of India under the Pradhan Mantri Swasthya Suraksha Yojna (PMSSY) to correct regional imbalances in quality tertiary level healthcare in the country and attain self-sufficiency in graduate and postgraduate medical education.

AIIMS Jodhpur Vacancy Details:

Total No of Vacancies: 01

The Vacancies are in the Department of Community Medicine and Family Medicine.

The Last date of submission for online application is 4th AUGUST 2025.

For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link:
https://medicaljob.in/jobs.php?post_type=&job_tags=aiims+jodhpur&location=&job_sector=all

Instructions for eligible candidates:-

The aspiring applicants satisfying the eligibility criteria in all respect can submit their application only through ON-LINE mode. The On-line registration of the application is made available on AIIMS, Jodhpur official website i.e. http://www.aiimsjodhpur.edu.in. Last Date for submission of online application is 04th, August, 2025 (till 05:00 PM). No Documents including online application form is required to be sent, however, all the applicants are advised to keep a copy of online application form with them, along with proof of payment (a Copy of challan /online payment receipt) for their record.

AIIMS, Jodhpur decision final:-

The decision of the AIIMS, Jodhpur in all matters relating to eligibility, acceptance or rejection of the applications, penalty for false information, mode of selection, conduct of examination(s), allotment of examination centers, selection and allotment of posts/organizations to selected candidates will be final and binding on the candidates and no enquiry / correspondence will be entertained in this regard.

Information for Candidates:-

(i) The All-India Institute of Medical Science is an autonomous body established under Act of parliament.

(ii) Service under the Institute is governed by that Act and the Rules & Regulations framed there under.

(iii) Tenure: The appointment is purely on contract basis initially for a period of 01 Years. This appointment will not vest any right to claim by the candidate for regular appointment or permanent absorption in the institute

OR for continued contractual appointment which may be renewed or terminated as decided by the Institute.

(iv) The applicants, who do not have requisite qualifications up to the last date for submission of applications, will not be considered.

(v) Incomplete application(s) will not be considered.

(vi) Closing Date 04th, August, 2025 (upto 5.00 PM).

(vii) The post(s) is/are whole time and private practice of any kind is prohibited.

(viii) The Candidate are likely to be posted at rural health and urban center attached with the institute for the period to be decided by the Institute as applicable.

(ix) AIIMS reserves the rights to increase or decrease the number of vacancies.

(x) Canvassing of any kind will be a disqualification.

(xi) The candidate should not have been convicted by any Court of Law.

(xii) In case any information given or declaration by the candidate is found to be false or if the candidate has willfully suppressed any material information relevant to this appointment, he/she will be liable to be removed from the service and any action taken as deemed fit by the appointing authority.

(xiii) The Competent Authority reserves the right of any amendment, cancellation a n d changes to this advertisement as a whole or in part without assigning any reason or giving notice.

(xiv) The decision of the competent authority regarding interview, verification of documents and selection would be final and binding on all candidates. No representation correspondence will be entertained in this regard.

(xv) All disputes will be subject to jurisdiction of Court of Law at JODHPUR.

Also Read:AIIMS PATNA JOBS 2025: Apply For JR Post Vacancies, Check Last Date Here

Powered by WPeMatico

Health Bulletin 02/August/ 2025

Here is the top health news for today: 

Rs 76 lakh compensation slapped on 6 Doctors, hospital for medical negligence

The District Consumer Disputes Redressal Commission, Thanjavur, recently directed a Tambaram-based private hospital and its six doctors (including an orthopaedic surgeon, a surgeon, 3 Anaesthetists, and a plastic surgeon) to pay Rs 76 lakh compensation to a patient, who became disabled after undergoing treatment at the hospital.

After undergoing six surgeries at the hospital, the complainant/patient was diagnosed with a compartment syndrome and foot drop. The complainant became 50% disabled, requiring the assistance of a round-the-clock attendant.

The history of the case goes back to 2022, when, after meeting with a two-wheeler accident, the complainant was diagnosed with a fracture in his right knee. On the same day i.e. 15.09.2022, the complainant was admitted to Kasthuri Hospital, Thambaram. The doctors diagnosed a normal ECG, a normal Doppler study of the right lower limb arteries, no evidence of stenosis in the arteries, and right lower limb no deep vein thrombosis. After assessing the complainant, the treating doctor- an orthopaedic surgeon, found no signs of compartment syndrome.

For more information, click on the link below:

Rs 76 lakh compensation slapped on 6 Doctors, hospital for medical negligence

NMC approves conditional renewal to 22 GMCs in Karnataka

In a major relief for the undergraduate medical education in Karnataka, the National Medical Commission (NMC) has granted conditional renewal and recognition to 22 government medical colleges in Karnataka, which had earlier received show-cause notices from the Commission for deficiencies in infrastructure and faculty requirements.

While granting conditional renewal and recognition to these medical colleges for the academic year 2025-2026, the Apex Medical Commission gave them four months to comply with the NMC standards.

Even though the Commission has not imposed any penalties on any of these 22 GMCs this year, they have been issued warning that admissions will be restricted for the next academic year if the system is not rectified.

Medical Dialogues had previously reported that earlier this year, NMC had issued show-cause notices to 22 government medical colleges in Karnataka for failure to meet standard parameters, including infrastructure and faculty recruitment.

For more information, click on the link below:

NMC grants conditional renewal to 22 GMCs in Karnataka

Delays Hit PGI’s Sarangpur Satellite Centre

A long-awaited healthcare expansion project in Chandigarh, aimed at reducing the heavy patient load on the Post Graduate Institute of Medical Education and Research (PGIMER), continues to face major delays despite multiple approvals and the official transfer of land nearly four years ago.

The Sarangpur satellite centre project, originally proposed in 2017, involves the development of a sprawling 50.76-acre campus intended to house a new MBBS college, advanced treatment centres, and speciality hospitals. The Union Cabinet approved the transfer of the land to PGI in 2019, but the Chandigarh administration only officially handed over possession in November 2021 after prolonged discussions.

Medical Dialogues had previously reported that in a major setback, the Postgraduate Institute of Medical Education and Research, Chandigarh (PGI Chandigarh) has failed to complete the project of the 300-bed hospital at Sangrur within the stipulated timeframe. With the deadline being missed, PGIMER has now set December 2019 as the new deadline for the completion of the hospital at its satellite centre.

For more information, click on the link below:

PGI’s Sarangpur Satellite Centre faces delays despite land transfer

AIIMS Patna Resident doctors accuse MLA of assault, go on strike

Resident doctors at the All India Institute of Medical Sciences (AIIMS) Patna went on a strike on Friday against the alleged manhandling of hospital staff by Sheohar MLA Chetan Anand. The incident reportedly escalated into a scuffle after the MLA’s supporters allegedly attempted to enter the hospital premises. When security personnel attempted to stop them, a heated exchange broke out between the two sides.

Healthcare services were affected at AIIMS Patna on Friday as resident doctors boycotted work in protest against the alleged high-handedness of Sheohar MLA Chetan Anand.

In a letter to the medical superintendent of AIIMS Patna, the Resident Doctors’ Association (RDA) sought legal action against Anand and the deployment of security personnel on the hospital premises.

“The MLA, his wife and his armed guards forcibly entered the hospital area, physically assaulted security staff, threatened resident doctors with death and brandished a firearm within hospital premises. A hospital guard was brutally injured and resident doctors were subjected to threats and abuse inside their own workplace,” the RDA alleged in the letter, according to a PTI news report.

For more information, click on the link below:

AIIMS Patna Scuffle: Resident doctors strike over alleged MLA Misconduct

Powered by WPeMatico

Biodeal Told To Justify Novel Delivery Claim In NPPA Exemption Plea For Midazolam Nasal Spray

New Delhi: Biodeal Pharmaceuticals Limited has been directed by the National Pharmaceutical Pricing Authority (NPPA) to submit documents supporting its claim regarding a novel drug delivery system before a final decision can be made on its application for exemption under Para 32(iii) of the Drug Price Control Order (DPCO), 2013, for Midazolam Nasal Spray 1.25% w/v.

The recommendation came during the 69th Multidisciplinary Committee of Experts meeting held on July 3, 2025, where the NPPA reviewed the firm’s exemption request and noted that “the Committee directed that the applicant to provide the documents in support of their claim w.r.t. new delivery system.”

The company applied for price control exemption claiming the formulation was “developed in-house through indigenous research and development involving new drug delivery system.”

However, the committee noted that “Midazolam Nasal Spray 1.25mg/actuation is a scheduled formulation under NLEM 2022 mentioned at Sections 1.3.3 & 5.1.7 of Schedule I of DPCO, 2013.” The current ceiling price effective from April 1, 2025, is Rs. 220.59 per ml, notified via S.O. 1489(E) dated 27.03.2025.

This application was a follow-up to NPPA’s earlier direction in the 68th meeting on June 3, 2025, wherein the firm was asked to present a product demonstration. Complying with the direction, the representative of Biodeal demonstrated the product and submitted the following key points:

“The product has been approved by DCGI as new drug for new indication i.e. Seizure clusters, acute repetitive seizure.”

“The approved pack is for 1.2ml pack size and each actuation contains 1.25mg of the drug. The pack contains 12 actuations, out of which initial 4 sprays needs to be primed in the air, 4 sprays remain in the bottle undelivered. The artwork of the cartoon also claimed delivery of 4 actuation.”

“Applicant submitted that there is no comparator product in the market having same label claim i.e., 4 metered doses.”

“The company has also stated that Midazolam spray 1.25% w/v was never approved by DCG(I) earlier for sales and distribution in the country of India and Midazolam nasal spray is not available in the market.”

The committee, however, disputed this claim, stating:

“Midazolam spray 1.25% w/v is an essential drug under NLEM 2022 and hence has been approved by DCGI. Therefore, the contention that Midazolam spray 1.25% w/v was never approved by DCG(I) earlier for sales and distribution seems incorrect.”

While the company submitted documentation to support its R&D claims, including a DSIR-accredited indigenous research facility, the panel expressed concern about whether the product truly qualifies as a “new delivery system” under Para 32(iii) of DPCO:

“The Committee inquired as how the applicant’s product is a new delivery system as other sprays are also there in the market for this formulation.”

Accordingly, the committee concluded that a decision could not yet be taken and directed the applicant to provide further supporting evidence:

“The Committee directed that the applicant to provide the documents in support of their claim w.r.t. new delivery system.”

Powered by WPeMatico

CDSCO Panel Accepts Phase I Trial Data for Intas’ Denosumab Biosimilar

New Delhi: The Subject Expert Committee (SEC) under the Analgesic and Rheumatology division of the Central Drugs Standard Control Organisation (CDSCO) has reviewed and accepted the final Clinical Study Report (CSR) submitted by Intas Pharmaceuticals Ltd. for its proposed biosimilar Denosumab 120 mg/1.7 ml injection, without raising any objections.

The development was discussed during the SEC meeting held on June 24, 2025, under file number E-54043. The CSR presented data from a Phase I, randomized, double-blind, three-arm, balanced, single-dose, parallel-group clinical trial, conducted under Protocol No. 0568-19. The study aimed to establish pharmacokinetic (PK) and pharmacodynamic (PD) comparability between Intas’ biosimilar Denosumab and the reference biologics Xgeva® from Amgen Inc., USA, and Amgen Europe B.V., The Netherlands.

The trial enrolled healthy adult male volunteers and evaluated bioequivalence and safety of the biosimilar candidate in a controlled setting, an essential step in the development of monoclonal antibody-based biosimilars.

Denosumab is a fully human monoclonal antibody targeting RANKL (Receptor Activator of Nuclear factor Kappa-Β Ligand), an essential regulator of osteoclasts, which are responsible for bone resorption. The reference product, Xgeva®, is widely approved for preventing skeletal-related events (SREs) in patients with bone metastases from solid tumors, as well as giant cell tumor of bone and hypercalcemia of malignancy.

Intas Pharmaceuticals Ltd., based in Ahmedabad, Gujarat, is a vertically integrated pharmaceutical company known for its strong biologics and biosimilars pipeline. The company has a wide global presence across North America, Europe, and Asia, and is committed to providing high-quality, affordable therapies in critical areas like oncology, rheumatology, and nephrology.

Powered by WPeMatico

Medical Bulletin 02/August/2025

Here are the top medical news for the day:

Non-Invasive Saliva Test May Detect Early Signs of Diabetes and Obesity: Study Finds

A new study published in Applied Physiology, Nutrition, and Metabolism has found that insulin levels in saliva can be used as a non-invasive method to detect early signs of metabolic health issues, including Type 2 diabetes, obesity, and heart disease.

Hyperinsulinemia, or elevated insulin levels in the blood, is a well-established marker of poor metabolic health and a predictor of chronic diseases. While blood testing has been the standard, researchers now say that saliva testing could serve as a practical and less invasive alternative.

The study involved 94 healthy participants with a range of body sizes. After fasting, each participant consumed a standardized meal-replacement shake, provided saliva samples at multiple time points, and completed a finger-prick blood glucose test. Researchers found that individuals living with obesity had significantly higher saliva insulin levels compared to leaner participants, even though their blood glucose levels remained similar.

Dr. Hossein Rafiei, co-author of the study, highlighted another compelling finding: some lean participants also showed large spikes in saliva insulin after the meal. “The finding that some people who are lean have high insulin is intriguing. This indicates that saliva insulin may be more useful than measuring someone’s weight or waist size.”

The study also found that waist circumference had the strongest correlation with elevated saliva insulin, more so than BMI, age, or sex. “Our results also suggest that saliva insulin may be better than blood glucose at distinguishing between those who are more metabolically healthy and those who are more likely to live with hyperinsulinemia,” adds Dr. Rafiei.

Researchers hope this method could eventually lead to accessible screening tools that enable early interventions—well before chronic conditions take hold.

Reference: Hossein Rafiei and Jonathan Peter Little. 2025. Saliva insulin concentration following ingestion of a standardized mixed meal tolerance test: influence of obesity status. Applied Physiology, Nutrition, and Metabolism. 50: 1-8. https://doi.org/10.1139/apnm-2024-0532

Study Reveals Artificial Sweetener May Weaken Cancer Immunotherapy

A new study published in Cancer Discovery, a journal of the American Association for Cancer Research, has found that high consumption of sucralose—a common artificial sweetener—may impair the effectiveness of immunotherapy in cancer patients. Researchers reported that patients with melanoma or non-small cell lung cancer who consumed high levels of sucralose had worse outcomes and reduced survival compared to those with lower intake.

Sucralose is widely used as a sugar substitute in diet sodas, coffee, and other low-calorie foods. While often chosen for its ability to help manage blood sugar and weight, this new research suggests it may have unintended consequences for cancer patients undergoing immune checkpoint inhibitor therapies such as anti-PD1 treatment.

To explore this link, researchers used mouse models of adenocarcinoma and melanoma. They found that sucralose disrupted the gut microbiome, increasing bacteria that degrade arginine—an amino acid critical for T cell function. This reduction in arginine led to less effective immune responses and poorer tumor control. “When arginine levels were depleted due to sucralose-driven shifts in the microbiome, T cells couldn’t function properly,” explained lead author Dr. Abby Overacre. “As a result, immunotherapy wasn’t as effective in mice that were fed sucralose.”

However, the researchers also discovered a promising workaround. Supplementing sucralose-fed mice with either arginine or citrulline—a compound that the body converts into arginine—restored the effectiveness of immunotherapy. “That’s why it’s so exciting that arginine supplementation could be a simple approach to counteract the negative effects of sucralose on immunotherapy,” Overacre added.

To test the relevance in humans, the team analyzed dietary data from 132 cancer patients undergoing anti-PD1 therapy. Those with higher reported intake of sucralose-containing foods and drinks had consistently poorer responses across various cancer types and treatment combinations.

A clinical trial is being planned to test citrulline supplementation in patients receiving immunotherapy.

Reference: Kristin M. Morder, Madison Nguyen, Drew N. Wilfahrt, Zakaria Larbi. Dahmani, Ansen BP. Burr, Bingxian Xie, Michael Morikone, Hector Nieves-Rosado, William G. Gunn, Drew E. Hurd, Hong Wang, Steven J. Mullett, Kaitlin Bossong, Stacy L. Gelhaus, Dhivyaa Rajasundaram, Lawrence P. Kane, Greg M. Delgoffe, Jishnu Das, Diwakar Davar, Abigail E. Overacre-Delgoffe; Sucralose consumption ablates cancer immunotherapy response through microbiome disruption.. Cancer Discov 2025; https://doi.org/10.1158/2159-8290.CD-25-0247

New Tool Can Calculate Heart Age and Reveal Hidden Cardiovascular Risks: JAMA

Your heart could be aging faster than the rest of your body, according to new research published in JAMA Cardiology. The study, conducted by researchers at Northwestern University Feinberg School of Medicine, found that many U.S. adults have a “heart age” several years older than their actual age. The age gap, the researchers noted, is even more pronounced in men than in women.

To make these findings more accessible and actionable, the research team developed a free online tool called the PREVENT Risk Age Calculator. This tool estimates a person’s heart age based on key health information such as cholesterol levels, blood pressure, BMI, medications, smoking habits, and diabetes status. Instead of presenting risk as a percentage, the calculator expresses it as an age, making it easier to understand.

“Heart age, or PREVENT age, may be particularly useful for patients and clinicians and be more effective in preventing heart disease,” said senior author Dr. Sadiya Khan, the Magerstadt Professor of Cardiovascular Epidemiology at Northwestern. “It translates complex information about the risk of heart attack, stroke or heart failure over the next 10 years into a number that is easier to understand and compare with one we are all familiar with – your actual age.”

To validate the tool, researchers analyzed health data from over 14,000 adults aged 30 to 79 who had no prior history of cardiovascular disease. They calculated heart ages and compared them to the participants’ real ages. The findings showed that the average heart age among women was 55.4—nearly four years older than their chronological age of 51.3. Men, on the other hand, had an average heart age of 56.7, seven years higher than their chronological age of 49.7.

While Dr. Khan noted that a one- or two-year gap may not be significant, a difference of five years or more could be cause for concern. “We hope this new heart age calculator will help support discussions about prevention and ultimately improve health for all people,” he said.

Researchers acknowledged that the definition of “optimal risk” could affect results and that wider testing is needed to determine how easily the tool is understood and adopted in clinical settings.

Reference: Krishnan V, Huang X, Perak AM, et al. PREVENT Risk Age Equations and Population Distribution in US Adults. JAMA Cardiol. Published online July 30, 2025. doi:10.1001/jamacardio.2025.2427

Powered by WPeMatico